DEBRA Research GmbH, a non-profit organization focused on advancing research, advocacy, and support for those affected by Epidermolysis Bullosa (EB), and LEO Pharma are partnering to accelerate the development of new therapies for EB.
There are currently no approved treatment options for EB.
“We are pleased to announce our non-exclusive partnership with LEO Pharma, which has demonstrated a strong track record in developing medicines for hard-to-treat skin conditions,” says Prof. Hubert Truebel, MD, MBA, Managing Director at DEBRA Research, in a news release. “This collaboration provides an excellent opportunity for us to combine our expertise and resources, enabling us to make meaningful advancements in the battle against EB. We are excited about the potential impact of this partnership and look forward to exploring similar opportunities with organizations that share our commitment to delivering life-changing treatments for EB.”
DEBRA Research operates globally as the research arm of DEBRA Austria.
“Having personally cared for patients with severe epidermolysis bullosa, I have experienced the devastating consequences firsthand. This is exactly the kind of high unmet need, where LEO Pharma strives to develop a treatment solution that can make a fundamental difference for the patients,” says Dr. Jacob Pontoppidan Thyssen, Chief Scientific Officer & Executive Vice President at LEO Pharma. “At LEO Pharma, we build partnerships that help us stay on the lookout and contribute our expertise to the next advancements. We are proud to collaborate with DEBRA Research, whose vast experience in the pharmaceutical industry and commitment to advancing medical research are invaluable. Together, we can do so much more.”
